Answers are grounded in this paper and cite their sources.
In vitro study demonstrates enhanced cell adhesion and differentiation in colorectal cancer cells following BRAF inhibition, suggesting therapeutic potential beyond cell killing.
BRAF inhibitor monotherapy appears to be ineffective in BRAF (V600E)-positive colorectal cancer (CRC) as a result of inherent EGFR-mediated resistance mechanisms. This concept initiated combinatorial treatment approaches. Nevertheless, BRAF inhibition in isogenic CRC cell lines induced enhanced cell-cell adhesion and differentiation, underlining a potential benefit of BRAF inhibitors in CRC.
No takes yet. Share an insight, caveat, or question.
Herr et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: